An implantable device for monitoring and controlling the sympatho-vagal activity

Abstract: A device for controlling therapeutic means (D) acting on a patient (P) comprises means (2-4) for detecting the sympatho-vagal balance of the said patient (P) and processor means (4) for generating a control signal (9) for the said therapeutic means (D) combined in a circuit assembly which allows the device (1) to be implanted in the body of the said patient (P).

Description: Field of the invention The present invention is directed generally to the problem of providing means for producing updated information on the sympatho-vagal balance for the purpose of controlling a therapeutic sequence of pharmacological and/or electrical nature. Currently the measurement or detection of the sympatho-vagal activity is performed for the most part by external instruments. Introduction to the physiological aspects of the problem The heart performs a mechanical function modulated by the sympathetic and vagal nervous activity, with consequent variations in the cardiovascular and respiratory parameters. In particular, the sympathetic component generally has a stimulating effect, whilst the vagal component has a depressive effect on the cardiovascular and respiratory variables mentioned hereinabove. Moreover, the role of a predominant sympathetic action in the creation of arrhythmia and even as a potential primary cause of sudden cardiac arrest is widely reported in the literature. On the other hand, serious bradycardiac syndrome and hypotension may correspond to a dominant vagal action so that an important element in the balance of the cardiovascular system may be identified as the correct balance of these two actions. For example, it has been shown that the absence of the vagal component, or the equivalent predominance of the sympathetic component, in post-infarction patients is associated with a probability of death of 34% as against 9% of patients having a high vagal activity, both evaluated in the fourth year after the infarction (see the article "Decreased heart rate variability and its association with increased mortality after acute myocardial infarction" by Kleiger, Miller, Bigger, Moss - Am.J.Card. 1987; 59:256-262). In the same way, it is known that, although on the one hand excessive sympathetic activity is the element which makes the initiation of ventricular fibrillation easier, on the other hand, the defibrillation threshold falls significantly with an increase in the sympathetic activity. If one considers that there are various pharmacological possibilities (implantable pumps) or electrical possibilities (vagal stimulation or inhibition and sympathetic stimulation or inhibition, single and two-chamber cardiac stimulation and defibrillation) for controlling the components of sympatho-vagal activity, one understands the interest in a system which allows the continuous measurement of this latter with the consequent possibility of performing an effective therapeutic action. Description of the prior art Currently, the measurement of sympatho-vagal activity is carried out only with external instrumentation, by the following methods. - Valsalva procedure The patient performs a forced inhalation with open glottis through a rubber nozzle connected to a sphygmomanometer in such a way as to produce a pressure of 40mm of Hg for 15 seconds. Subsequently the patient is invited to breath normally through the nose. An analysis of variations in the heart rate during this exercise makes it possible to evaluate a parameter, called the Valsalva Ratio or VR, defined as the ratio between the greatest R-R interval in the reflex bradycardiac phase consequent on the effort exerted, and the shortest R-R interval observed during the exertion of the effort. The exercise in question evaluates both the response of the orthosympathetic system and that of the parasympathetic system. Values of VR ≥ 1.4 are considered normal. - Handgrip test The patient is invited to grip an arm brace of a sphygmomanometer in such a way as to generate a pressure of the order of 30% of the value of a maximum force. The parameters detected are the heart rate and diastolic arterial pressure, PAd, in three consecutive tests respectively in the first, second and third minutes of effort. This method enables the effectiveness of the operation of the orthosympathetic system to be evaluated: PAd increments of at least 16mm of Hg with respect to base values are considered physiological, whilst the heart rate must rise by at least 10% with respect to its base values. - Postural test The patient is initially in a clinostatic position and is invited to move to the standing position in less than three seconds and then to remain there for three minutes. The method enables the calculation of two indices correlated, respectively, with the minimum heart rate before the movement from the clinostatic position to the standing position, with the maximum rate following achievement of the standing position, as well as the minimum rate reached after about 30 seconds in the standing position. This test evaluates simultaneously the operation of the orthosympathetic and parasympathetic systems. - Heart beat/heartbeat analysis This test evaluates quantitatively the respiratory arrhythmia induced in the subject under test by his taking six deep breaths in one minute. Based on the heart rate trend recorded during the test, it derives the average of the variations in the heart rate between the maximum value, corresponding to the inhalation phase, and the minimum value, corresponding to the exhalation phase, for the six consecutive breaths taken. Normal values are greater than 15 bpm. The test is very useful for an evaluation of the operation of the parasyapathetic system. All four methods described up to now are explained, for example, in the volume "La valutazione strumentale della funzionalita del sistema nervoso vegetativo" di Cugnoli, Bongiovanni, De Grandis, Serra - Appunti di Elettromiografia Clinica, Verona, Bi & Gi Editori, 1987 (authors: Arrigo, De Grandis, Serra). - Power spectral density This method makes it possible to evaluate a sympatho-vagal balance index directly. The technique in question is based on a record taken over several minutes, typically 20, of spontaneous cardiac activity either extracted from a Holter recording, or taken directly from a patient under standard conditions such as, for example, controlled frequency respiration. The processing algorithm performs a spectral analysis on the trend signal of atachogram of the stored cardiac periods. Two spectral components are typically displayed: one of high frequency, for example 0.25 Hz, and one of low frequency, for example 0.1 Hz. The high-frequency component represents a quantitative evaluation of the respiratory arrhythmia and depends principally on the efferent vagal activity. The low frequency component is correlated to the so-called Mayer waves which represent fluctuations in the heart rate trend with a period of the order of 10 seconds; this component is however linked both to the vagal and to the sympathetic efferent activity. The sympatho-vagal balance index is the ratio between the low frequency and high frequency components. Reference may be made to the article "Power spectral analysis of heart rate variability and arterial pressure variabilities as a marker of sympatho-vagal interaction in man and conscious dog" by Pagani, Lombardi, Guzzetti, Rimoldi, Furlan, Pizzinelli, Sandrone, Malfatto, Dell'Orto, Piocaluga, Turiel, Baselli, cerutti, Maliani - Circulation research 1986; 59: 178-193. Standard deviation of the R-R intervals This method is typically applicable to 24-hour Holter recordings. The sympatho-vagal balance is expressed quantitatively by means of the variability of the heart rate interpreted as the standard deviation of the R-R intervals from the average value evaluated in a predetermined time interval. In the case of a 24-hour Holter analysis, the time interval considered is typically one hour so that the standard deviation of the R-R intervals is provided hour by hour relative to the average value evaluated in the same time interval. An increase in the sympathetic activity (or a reduction in the vagal activity) is typically associated with a reduction in the variability of the heart rate as defined above. In this respect see the article by Kleiger, Miller, Bigger, Moss mentioned above. - Method of analysis of the variability of the heart rate by comparison of consecutive periods This method is also utilised typically for analysis of 24-hour Holter recordings. The sympatho-vagal balance is expressed by means of the variability of the heart rate expressed as the number of R-R intervals which, in a given time interval, differ from the preceding interval by at least a predetermined quantity. Typically the reference time interval is one hour and the discrimination threshold between two consecutive R-R intervals is 50 ms. Therefore, in this case, the number of R-R intervals which differ from the preceding interval by at least 50 ms is provided hour by hour. A high sympathetic activity or a depressed vagal activity causes a reduction in the variability of the heart rate defined as above. In particular, hourly values of the order of 200 when awake and 400 during sleep are considered normal. In this respect see the article "New method for assessing cardiac parasympathetic activity using 24 hour electrocardiograms" by Ewing, Neilson, Trevis in Br. Heart J. 1984; 52: 396-402. It should also be stressed that this latter method has the advantage over the previous one of distinguishing the contribution of the vagal nervous system from that of the sympathetic system more markedly. This is linked to the fact that considerable differences between consecutive R-R intervals, that is to say, a high variability expressed according to this latter method, is also seen as a high variability according to the preceding method, whilst the contrary is not always true. These two methods are therefore not equivalent. This fact is for example found in patients having significant variations in heart rate compared with the average value in the time interval under consideration, but with small variations, for example < 50 ms, between consecutive R-R intervals: in this situation the standard deviation will be consistent whilst the variability related to variations between consecutive periods will be low. As may be noted, all the methods described above lend themselves to being utilised only with the aid of significant external instrumentation and/or sophisticated calculation systems not compatible with the current technology for implantable devices, in effect making continuous monitoring of the sympatho-vagal balance, and consequent control of therapeutic action, impossible. In particular, the methods applied to the 24-hour Holter recordings exploit sophisticated algorithms for recognising arrythmia and anomalous heartbeats in general, in order to eliminate from the processing those parts of the electrocardiogram in which such events are present. In general it is a good rule to apply the analysis to specimens of the ECG with less than five extrasystoles per hour and this underlines the importance of the recognition of anomalous cardiac events. More specifically, the present invention relates to a device according to the preamble of Claim 1, which is known, e.g. from SCHALDACH: "PEP-gesteuerter Herzschrittmacher", BIOMEDIZINISCHE TECHNIK, vol. 34, no. 7/8, 1 july 1989 - 1 August 1989, BERLIN DE, pages 177-184; (XP000050247). Objects and summary of the invention The object of the present invention having the further features set forth in Claim 1 is to provide a device which is implantable so as to be able to measure sympatho-vagal activity in a continuous manner and with time constants such as to allow the possible piloting of a pharmacological and/or electrical therapeutic action, effected preferably by means of a separate implantable device connected to the first or integrated in the latter so as to form a single implantable assembly. According to the present invention this object is achieved by a device having the characteristics set out specifically in the following claims. In summary, the basic parameter which is utilised is the variability of the heart rate evaluated as the number of consecutive R-R intervals which differ from one another by at least a minimum threshold which is programmable and related to the programmed time interval. From this point of view the invention is conceptually similar to the method of analysis of the variability by comparison of consecutive periods described hereinabove. The solution of the invention is however distinguished from this known technique by the following characteristics. i) The method of detection is based on timing rather than morphology. ii) The method of detecting the electrocardiology signal is based on selective intracardiac sensing rather than on general surface electrodes. iii) Continuity of the measurement and testing of the sympatho-vagal balance without the temporal limits imposed by the Holter analysis. iv) The complete difference in technology between an external system and an implantable one is well known to those skilled in this particular field. As previously mentioned, it is important to exclude anomalous cardiac events from the analysis of the variability of the R-R intervals. Known methods which use Holter analysis succeed in recognising ventricular extrasystoles by means of complex algorithms for the morphological analysis of the recorded signal. This is possible thanks to the fact that the surface ECG depends morphologically on the sense and direction of propagation of the overall myocardiac depolarisation and subsequent repolarisation. This morphology thus depends on the point at which the cellular depolarisation starts and on the direction of propagation followed, according to the well-known Einthoven theory. The situation is however totally different as regards the electrocardialogy signal detected within the heart: this signal has an almost constant morphology for each type of cardiac event, the detection being of the point type, that is to say, localised in the region surrounding the sensing electrode itself. It is therefore not possible, in this situation, to rely on morphological analysis for the recognition of ventricular extrasystoles as is done with known external techniques. However, by utilising both atrial and ventricular sensing, as envisaged in our invention, a ventricular extrasystole is recognised thanks to the fact that this is not preceded by an atrial event but rather by another ventricular event. The recognition of anomalous ventricular events therefore differs completely according to whether the device utilised for the detection and analysis of the electrocardiologicy signal is outside or inside the human body. It should also be noted that external recording devices can suffer to a very much greater extent than implantable systems from electromagnetic interference, from myopotentials, and from movements of the patient in general. The use of intracardiac electrodes for the detection of the electrical activity of the atrium and of the ventricle represents a guarantee of the correct recording of these events: the reliability of the consequent processing is therefore greater than that carried out by external instruments, More than this, it should be stressed that the implantable device carries out an analysis of the variability of the heart rate, and hence of the sympatho-vagal balance, continuously, and in real time, the only temporal limit being linked to the exhaustion of its energy supply which happens typically only after several years. This fact is directly connected to the technology utilised in implantable devices which use highly reliable, low-power circuits. Even the technological problems are therefore very different from those of external apparatus: for example an electrocardiograph does not have to respect absolute limits of energy consumption and dimensions comparable with those of an implantable object which must necessarily be of small dimensions for the patient and must require an operating energy which is so low that it can operate for several years. Finally, it is emphasised that the implantable device is able to intervene on the patient at any moment, whenever it is considered necessary, by actuating the therapeutic device associated with the sensing system. In particular, if a threshold of for example 50 ms and a processing interval of 1 minute are set, a device according to the invention is able to provide, minute by minute, a number of consecutive R-R intervals which differ by at least 50 ms. It is moreover possible to set a discrimination threshold in percentage terms with reference to the preceding period, rather than an absolute threshold: for example, it is possible to count, minute by minute, the R-R intervals which differ by more than 6.25% with respect to the preceding R-R interval. This possibility can also, optionally, be rendered programmable. Still by means of programming (according to criteria known per se) it is possible to exclude positive or negative variations of consecutive R-R intervals from the count or to have them both in separate form, independently of the programmed threshold and independently of whether this threshold is of absolute or percentage type. The possibility of separating the positive variations from the negative variations of the consecutive R-R intervals can be useful in relation to the fact that an increase in the heart rate can be associated directly with a momentary dominance of the sympathetic activity over the vagal activity, whilst a reduction in the heart rate can be associated directly with a momentary dominance of the vagal activity over the sympathetic activity so that the device can be made sensitive only to variations in the sympathetic activity or to those of the vagal activity. Moreover, two-chamber sensing constitutes an essential element for any discrimination of anomalous events, permitting correct evaluation of the sympatho-vagal balance, that is, unaffected by premature heart beats. Finally it is noted that the solution described has no connection with the cardiac acceleration parameter expressed as the maximum acceleration of the spontaneous heart rate, used as a prognostic parameter for the possibility of onset of tachycardia or ventricular fibrillation. Detailed description of the invention The invention will now be described purely by way of non-limitative example with reference to the attached drawings, in which: Figure 1 illustrates in schematic outline the general arrangement of use of a device according to the invention; and Figure 2 is a detailed illustration of the internal structure of the device according to the invention in the form of a block circuit diagram. In Figure 1 the reference numeral 1 generally indicates a device for measuring the sympatho-vagal activity which is intended to be implanted in the body of a patient P. The device 1 is intended to operate together with a therapeutic device D, preferably also implantable and, if appropriate, integrated with the device 1 and intended to act on the patient either pharmacologically and/or electrically in dependence on the sympatho-vagal activity measured by the device 1. As an indication, the device D can, for example, be constituted by a neurological stimulator or by a device for delivering doses of pharmaceuticals such as, for example, the commercial products produced by the United States company Medtronic Inc.of Rice Creek Center 7000, Central Avenue N.E, Minneapolis, USA. In any case, the characteristics and mode of operation of the device D are considered generally known and therefore not such as to necessitate a detailed description here. Above all, the characteristics of the device D, as well as the manner of association thereof with the body of the patient P, are not relevant to an understanding of the invention. In general, the device 1 is provided with input terminals 2 on which an electrocardiology signal (ECG) is present. Preferably (see also the block diagram of Figure 2) an atrial ECG electrode 2a and a ventricular ECG electrode 2b can be provided, both leading to an analog-to-digital interface 3. The interface 3 transfers the signals provided by the electrodes 2a and 2b, converted into digital form, to the input of a microprocessor 4. This latter, together with respective memories, for example of the ROM 5 and RAM 6 type, forms a control and processing system generally indicated 7 which has an associated internal clock 8 and an output interface module 9 intended to pilot the therapeutic device D via respective output terminals 10. The reference numeral 11 generally indicates a bi-directional telemetry device comprising a reception/transmission interface 12 connected to the microprocessor 4 as well as a radio-frequency receiver-transmitter 13 connected in bi-directional transmission relationship with the interface 12 leading to a receiver-transmitter aerial 14. The processing and control circuit 7 supervises all the operating phases of the device and processes the data coming from the adjacent interfaces. To this end, the ROM memory 5 preferably functions as a program memory whilst the RAM memory functions as a processor and store for data programmed and stored by the microprocessor 4 itself in dependence on the processing performed. The receiver-transmitter 11 (telemetry device) effects an exchange of information between an external programmer device 15 and the control system 7. In particular, it performs the functions of receiving programmed parameters from the outside and transmitting values stored in the RAM memory. Typically, the data transmitted relate to parameters processed by the system after measurement has been effected or after checking for correct dialogue between the external programmer and the implanted device. The transmission and reception of data between the implantable device and the external programmer, as already mentioned, occurs at radio frequency. This is entirely according to technical characteristics well known per se to the man skilled in the art. The internal clock 8, which is also programmable, is able to provide the processing system with the clock reference essential for an evaluation of a normal measurement of the sympatho-vagal activity. The analog-to-digital interface 3 is typically provided with atrial and ventricular sensing circuits which are able to recognise the electrical activities of the atrium and of the right ventricle and to discriminate against interference from other sources. The signals representing the information sensed are transmitted in digital form to the processing and control system 7 which utilises them for the purpose of prognosis and/or therapy according to its inherent processing algorithm according to the values of the programmed parameters. This interface therefore puts the sensing catheter or catheters 2a, 2b into communication with the information processing and control device 7. In particular the sensing devices 2a, 2b are made by the same technology as that used in current cardio-electrostimulators for performing the same function. The output interface 9 transmits the intervention command to the therapeutic device D together with the values of the parameters which quantify the magnitude of the evaluated sympatho-vagal imbalance, thus permitting the therapeutic device to operate in an optimal manner. As a basic consideration it should again be noted that the individual circuits forming the blocks 3 to 15 are individually known per se. In its fundamental aspect the invention is based on criteria adopted for the analysis of electrocardialogy signals picked up through the catheters 2a, 2b. In particular this action can be effected with two individual monopolar or bipolar catheters or with a single catheter which could be provided with two or four electrodes respectively, intended in each case to be located close to the atrium and to the right ventricle. The knowledge both of the atrial signal and of the ventricular signal allows the system to discriminate between the instantaneous sinusal heart rate and momentary, spurious frequencies which can result from the presence of arrythmia. The signal thus discriminated is sent to the processing and control system 7 which calculates the difference between the current R-R period and the preceding one and compares the result with a programmable threshold, typically of 50 ms. The events which exceed this value, defined as useful events, are counted, the count interval being programmable in discrete steps from a minimum of one minute to a maximum of one hour. The purpose of the system being to provide a signal which triggers a therapeutic device, particular attention must be given to the intervention criteria. For this purpose a normality band is defined within which the number of useful events counted must lie: this will vary over a 24 hour period in that the sympatho-vagal balance assumes different physiological values during the course of a day. In particular, during nocturnal hours, the vagal system typically dominates whilst, during the day, the sympathetic system typically dominates. The normality band has an upper limit linked to the maximum acceptable imbalance in favour of the vagal system whilst its lower limit corresponds to the maximum acceptable imbalance in favour of the sympathetic system. Consequently, the system includes the internal clock 8 which is programmable so as to associate the correct normality band, and consequently the correct intervention values, with each phase of the day. The possibility of telemetric communication of this data enables the optimum intervention conditions, which have to be personalised to the patient, to be evaluated in vivo. If it is found that the upper or lower limit of the normality band for the current hour is exceeded, the system enables the starting of the therapeutic procedure (the nature of which, as mentioned, does not constitute the subject of the present invention but may in any case be of pharmacological and/or electrical type). In each case, the therapeutic intervention device will receive both the data relating to the type of imbalance, that is, whether it favours the vagal or the sympathetic system, and a quantitative evaluation of the change: the therapeutic action may thus be metered according to the magnitude and type of sympatho-vagal imbalance. In particular, as already indicated above, by means of the microprocessor 4 it is possible to set a discrimination threshold in percentage terms with reference to a preceding period rather than an absolute threshold: for example, it is possible to count, minute by minute, the R-R intervals which differ by more than 6.25% from the preceding R-R intervals. This possibility can also, optionally, be made programmable. Again by programming of the microprocessor 4, it is possible to exclude either the positive or the negative variations of consecutive R-R intervals from the count or to have them both in separate form, whatever the programmed threshold and independently of whether this threshold is of the absolute or of the percentage type, so as to separate the positive variations of consecutive R-R intervals from the negative variations. The modes of operation and criteria which can be adopted for the programming of the microprocessor 4 to achieve the aforesaid objects are widely known to those skilled in the art and do not, therefore, need to be described herein.

Claims: A device for controlling therapeutic means (D) acting on a patient (P), including processor means (4) for generating a pilot signal (9) for the said therapeutic means (D) combined in a circuit assembly which allows the device (1) to be implanted in the body of the said patient (P), characterised in that it includes means (2-4) for detecting the sympatho-vagal activity of the said patient (P) which comprise electrodes (2a, 2b) which can be located close to the atrium and/or the right ventricle of the said patient (P), and in that: the said processor means (4) include memory means (6) for memorising at least one band of normality values for the said sympatho-vagal activity to enable the said therapeutic means (D) to be piloted when the detected sympatho-vagal activity departs from the said band of normality values, said normality band being defined as the band within which a number of useful events counted must lie, and the said processor means (1) detect the consecutive R-R intervals and then compare them with a rejection discrimination threshold, the events which exceed said treshold value being defined as said useful events. A device according to Claim 1, characterised in that the said device (1) is integrated with the said therapeutic means (D) in an assembly which can be implanted in the body of the said patient (P). A device according to Claim 1 or Claim 2, characterised in that it further includes transmission means (11) for transmitting signals indicative of the said sympatho-vagal activity to 'the exterior and/or reception means (15) for receiving from the exterior programming signals for programming the operation of the device (1) and/or the intervention of the said therapeutic means (D). A device according to Claim 1, characterised in that said rejection discrimination threshold, is of the order of 50 ms. A device according to any one of the preceding claims, characterised in that the said means for detecting the sympatho-vagal activity (4) are sensitive to the difference between anomalous and physiological heart beats whereby to measure the sympatho-vagal balance. A device according to Claim 1, characterised in that it includes timing means (8) for selectively varying the said band of normality values with the passage of tine. A device according to Claim 1, characterised in that the said processor means (4) can be set with a discrimination threshold preferably as a percentage with reference to the preceding period. A device according to Claim 7, characterised in that the said processor means (4) count, minute by minute, the R-R intervals which differ by more than a given percentage factor, for example 6.25%, with respect to the preceding R-R interval. A device according to Claim 8, characterised in that the said percentage factor is selectively programmable. A device according to Claim 8 or Claim 9, characterised in that the said processor means (4) exclude from the count positive or negative variations of the consecutive R-R intervals, or have them both in separate form, independently of the programmed threshold and independently of whether this threshold is of absolute or percentage type.

Inventors: CORBUCCI GIORGIO, CORBUCCI, GIORGIO
Applicants: SORIN BIOMEDICA CARDIO SPA, SORIN BIOMEDICA CARDIO S.P.A.
Application year: 1993
Main classification: A61N1
IPC codes: A61N1